Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis

Next Previous
Trial Profile

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FUTURE-2
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 01 Jun 2026 According to a novartis media release, data from this trial will be presented at the European Alliance of Associations for Rheumatology (EULAR) Congress on June 3-6 in London.
  • 14 Nov 2022 Results of post hoc (n=2504) pooled analysis from the FUTURE 2, 3, 4, 5 and MAXIMISE studies investigated the impact of different levels of HU, and history of gout/uric acid lowering therapy (ULT) on pts with PsA in terms of demographics, clinical characteristics, comorbidities, and clinical response to secukinumab over 1 year, presented at the ACR Convergence 2022.
  • 04 Jun 2022 Results of post hoc analysis included pooled data from PsA pts enrolled in the FUTURE 2-5 and MAXIMISE phase, evaluating the impact of HU on PsA in terms of clinical presentation, severity, comorbidities, and response to secukinumab (SEC) over 1-year, presented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top